Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 25, 2017

Boston Scientific releases new Resonate defibrillator systems

Boston Scientific has released its new Resonate implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices with the HeartLogic Heart Failure Diagnostic for heart failure (HF) management.

Boston Scientific has released its new Resonate implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices with the HeartLogic Heart Failure Diagnostic for heart failure (HF) management.

The US Food and Drug Administration (FDA) has approved the systems for conditional use in the magnetic resonance imaging (MRI) environment.

Designed to alert physicians of worsening HF, the new HeartLogic Diagnostic combines data from sensors used for heart sounds, respiration rate and volume, thoracic impedance, as well as heart rate and activity.

The alert feature is said to have demonstrated 70% sensitivity with the ability to deliver weeks of advance notice of an upcoming HF event.

Boston Scientific Rhythm Management and Global Health Policy senior vice-president and chief medical officer Kenneth Stein said: "The HeartLogic Diagnostic provides physicians with the ability to pivot from reactive heart failure treatment to proactive care with a goal of improving patient outcomes and reducing heart failure-related hospitalisations.”

Developed to improve patient management with personalised care, the defibrillators feature the firm’s SmartCRT with EnduraLife Battery Technology.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Using the Multisite Pacing capability for multi-electrode pacing, SmartCRT Technology allows customised use and placement of the device.

"The HeartLogic Diagnostic provides physicians with the ability to pivot from reactive heart failure treatment to proactive care with a goal of improving patient outcomes and reducing heart failure-related hospitalisations."

In combination with EnduraLife Battery, SmartCRT enables personalisation of the device based on individual patient needs.

The MR-conditional labelling of the devices facilitates full-body MR scans of patients implanted with these devices in 1.5 Tesla environments upon compliance with conditions of use.

Boston Scientific is currently enrolling patients in the MANAGE-HF study designed to further assess the HeartLogic Diagnostic.

The firm is also conducting various clinical trials to investigate improved CRT therapy response with the SmartCRT Technology.


Image: All Resonate devices feature the HeartLogic Heart Failure Diagnostic that could provide weeks of advance notice of an impending HF event. Photo: courtesy of Boston Scientific Corporation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU